This document presents the Q2 FY26 earnings results and strategic updates for Medtronic, a medical technology company. Key takeaways include achieving 5.5% organic revenue growth and 8% EPS growth, exceeding expectations across major segments like Cardiovascular. The company highlights its focus on enterprise growth drivers, such as new therapies for atrial fibrillation, hypertension, and the Hugo robotic-assisted surgery system. The information also details segment-specific revenue figures and operational milestones, alongside financial metrics, forward-looking statements, and the anticipated separation of its Diabetes business into a new standalone public company.